Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
There's a gap that needs to be filled...not sure when another PR will be out tho.
GBSN News out!!
https://finance.yahoo.com/news/great-basin-scientific-staph-id-123000135.html
Lab Results
Great Basin Scientific’s Staph ID/R Blood Culture Panel Clinical Evaluation and Rapid Identification Analysis Published in Journal of Clinical Microbiology
GlobeNewswire•February 15, 2017
SALT LAKE CITY, Feb. 15, 2017 (GLOBE NEWSWIRE) -- Great Basin Scientific, Inc. (GBSN), a molecular diagnostics company, today announced the Journal of Clinical Microbiology published results of a multicenter study that demonstrated the effectiveness of its Staph ID/R Blood Culture Panel in rapidly identifying several species of Staphylococci and in accurately detecting the mecA gene directly from a positive blood culture. The results of the study, which was conducted across three clinical sites, demonstrated the performance and efficacy of the Staph ID/R Blood Culture Panel compared to conventional methods, and concluded that the Company’s panel provided decreased time to results at a lower price, helping physicians diagnose and deliver a timely, accurate and cost-effective course of treatment.
“Bloodstream infection-related sepsis, including those caused by MRSA and other pathogenic Staphylococcus species, is not only a leading cause of morbidity and mortality in the U.S., but is also associated with over $17 billion in rising healthcare costs annually. Traditional blood culture methods provide physicians with a diagnosis 48 to 72 hours after a positive sample is identified, delaying appropriate treatment and putting the patient at further risk,” said Rob Jenison, chief technology officer and senior vice president of R&D at Great Basin Scientific. “Great Basin’s Staph ID/R Blood Culture Panel is proven to provide highly accurate and actionable results in under two hours. Our panel potentially eliminates 32 to 88 hours of inappropriate antibiotic therapy, thereby potentially reducing length of patient stay and improving patient care - creating time and cost efficiencies for hospitals and labs of all sizes.”
Led by Dr. Gerald A. Denys from the Department of Pathology & Laboratory Medicine at Indiana University, the study found that Great Basin’s Staph ID/R Blood Culture Panel correctly identified positive results for Staphylococcus species 99.4 percent of the time and negative results were correctly identified 99.9 percent of the time. Also, the mecA gene, a major drug resistance marker conferring resistance to methicillin and other beta-lactams and creating the superbug MRSA, was detected accurately from positive samples 99.7 percent of the time and negative results were properly identified 99.2 percent of the time. The results of this study also revealed that the Great Basin molecular assay was more effective than conventional biochemical and cefoxitin disk methods performed at an independent laboratory, with performance estimates at 95 percent confidence intervals (CI) across all three sites. The Company believes the Staph ID/R Blood Culture Panel is one of the most comprehensive Staphylococcus molecular tests currently on the market, in that it identifies Staphylococcus aureus, Staphylococcus lugdunensis and other Staphylococcus species to the genus level and detects the mecA gene in all Staphylococcal species from positive blood cultures.
“We’re so pleased by the positive findings of this study and are excited by the response from the market for our blood culture panel,” said Sandra Nielsen, senior vice president, sales, marketing and HR at Great Basin. “The results of this study illustrate our panel’s accuracy, cost-effectiveness and ability to deliver definitive and highly actionable information which we believe contribute to the increased adoption of our panel by a significant percentage of our installed customer base, as well as new and larger hospitals and labs.”
The Company announced the commercial launch of the Staph ID/R Blood Culture Panel in U.S. and Europe in September 2016, and the test also has CE mark designation under the European Directive of In Vitro Diagnostic Medical Devices.
Great Basin’s molecular diagnostics system offers low-plex (one to three analytes), mid-plex (four to six analytes) and multiplex (syndromic) testing, with commercial assays available for the detection of Shiga Toxin-producing Escherichia coli (STEC), Group B Streptococcus (GBS), Toxigenic Clostridium difficile (C. diff), and Staph ID/R Blood Culture Panel. Continuing the Company’s efforts to expand its menu of sample-to-result assays to diagnose infectious disease, Great Basin has five additional tests on their product roadmap, including a Stool Bacterial Pathogens Panel and a Bordetella Direct Test, both of which recently completed clinical trials and have been submitted to the U.S. Food & Drug Administration (FDA) for 510(k) clearance; and a Nasal S. aureus Pre-surgical Screen, Candida Blood Infections Panel, and CT/NG Test, which are currently in development.
GBSN
Thanks for the update.
Any updates here?
my L2 hasn't been working all day for me, has anyone had the same problem?
Thank you.
What does this mean for us shareholders?
MM's do this all the time
Hampton Sales 2013 2Q
http://www.elliman.com/pdf/e63e543d7210c849c5175a995463e27115fbfffa
Inventory fell as the number of sales
surged. There were 1,573 listings at the
end of the quarter, 12.5% below prior year
levels. Sales jumped 25.2% to 675 over the
same period, accelerating the absorption
rate by 30% to 7 months. This was
the 5th
consecutive quarterly year-over-year rise
in activity
someone is still buying incognito
someone is still buying incognito
can someone post a L2? TIA
yeah, we all have seen how thin this is.
someone has been loading up quietly in the last week or two
thanks for the update, willy4.
can someone post a L2 pls
this has revived.
didn't willy say there would be an update at the end of Sept??
HLXH
how' errrrrbody doing? anyone heard from willy?
still holding a position here
hey EB, new to ur board.
level 2 anyone? tia
hey Dollarland, can u post L2 please.
thx
HLXH
wow! from 16 boardmarks to 79 now...looking forward to the annual report.
HLXH
level 2 anyone?
HLXH
nice green close!
HLXH
HLXH financials coming soon and i'm excited!!
can someone post a chart of our lil gem. tia.
HLXH
HLXH never ceases to amaze me-awesome chart!!
holding long and strong here.
go HLXH!!
GM all HLXH longs!
can't wait to view the annual financials
HLXH
nice green close!
HLXH
great DD!
HLXH
Gm,
i picked up some march calls last friday.
DNDN
someone got very lucky w/ those cheapies that were picked up
HLXH
nice green close...still super undervalued tho.
have a great weekend HLXH longs!!!
HLXH
nice green close HLXH'ers
go HLXH!!!
and a mega thin float as well.
HLXH
this is one hott report! imo.
"Listing inventory fell sharply" there's more demand. imo.
this is great news!
HLXH
awesome!
HLXH
hope we don't get anymore bid whackers lol
HLXH!!!!
level 2, pls.
HLXH
another awesome undervalued and low floater: CVSL
check out the due dilligence on the cvsl board.
uplisting to big board nasdaq in 2013. imo and based on the dd.